You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 637 Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Immunotherapy toxicities
637 Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 202093014
Dec 20201907
Jan 20211402
Feb 20212604
Mar 20215808
Apr 20212407
May 2021203
Jun 2021006
Jul 2021106
Aug 2021003
Sep 2021009
Oct 202130018
Nov 202114016
Dec 20211408
Jan 20221401
Feb 20222403
Mar 20221401
Apr 20224602
May 20223007
Jun 20223000
Jul 20224801
Aug 20224605
Sep 20222000
Oct 20222800
Nov 20223603
Dec 20224001
Jan 20233800
Feb 20231200
Mar 20231801
Apr 20231004
May 20231401
Jun 2023800
Jul 20231602
Aug 20232203
Sep 20232200
Oct 20233002
Nov 20235401
Dec 20233601
Jan 20242002
Feb 20242601
Mar 20245401
Apr 20241601
May 20242000
Jun 20244402
Jul 20245001
Aug 2024803
Sep 20243207
Oct 20241808
Nov 20241603
Dec 2024804
Jan 2025604
Feb 2025004
Mar 2025009
Apr 2025005
May 2025003
Jun 2025003
Total12690211